Relevance of minor discrepancies at second pathology review in gynaecological cancer.

Ecancermedicalscience

Medical Oncology Department, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.

Published: May 2019

Aim: To determine the incidence of discrepancy rate between the initial pathology diagnosis and referral diagnosis in women with gynaecological cancer.

Methods: A retrospective observational study was performed including all consecutive patients with gynaecological cancer referred and who underwent pathologic review between January 2013 and May 2017. Discrepancies were minor when future treatment was not altered or major when the treatment was modified.

Results: A total of 259 patients were included. The original diagnosis was ovarian cancer ( = 126, 48.6%), endometrial cancer ( = 84, 32.4%), cervical cancer ( = 43, 16.6%) and vulvar cancer ( = 6, 2.3%). Eighteen women (6.9%) had major discrepancies and 69 patients (26.6%) had minor discrepancies. The main reason for the minor discrepancy was tumour grade or histology subtype. Regarding ovarian cancer, 13 out of 16 patients had minor discrepancies at histology subtype among serous, endometrioid, mucinous or undifferentiated tumours. The main issue for the minor discrepancy in patients with cervical cancer was among different subtype of cervical adenocarcinoma. Minor discrepancies due to tumour grade were also observed in 14, 19, 8 and 3 patients with endometrial, ovarian, cervical and vulvar cancer, respectively.

Conclusions: A second pathology review also adds valid information in those cases with minor discrepancies leading to a difference in patients´ counselling regarding follow-up and prognosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592709PMC
http://dx.doi.org/10.3332/ecancer.2019.929DOI Listing

Publication Analysis

Top Keywords

minor discrepancies
20
cancer
9
second pathology
8
pathology review
8
gynaecological cancer
8
ovarian cancer
8
cervical cancer
8
vulvar cancer
8
minor discrepancy
8
tumour grade
8

Similar Publications

Interpretation and classification of FBN1 variants associated with Marfan syndrome: consensus recommendations from the Clinical Genome Resource's FBN1 variant curation expert panel.

Genome Med

December 2024

European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), HTAD and MSA Rare Disease, Working Group, Paris, France.

Background: In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) developed standardized variant curation guidelines for Mendelian disorders. Although these guidelines have been widely adopted, they are not gene- or disease-specific. To mitigate classification discrepancies, the Clinical Genome Resource FBN1 variant curation expert panel (VCEP) was established in 2018 to develop adaptations to the ACMG/AMP criteria for FBN1 in association with Marfan syndrome.

View Article and Find Full Text PDF

Accurate control of force on the environment is mechanically necessary for many tasks involving the lower extremities. We investigated drifts in the horizontal (shear) active force produced by right-footed seated subjects and the effects of force matching by the other foot. Subjects generated constant shear force at 15% and 30% of maximal voluntary contraction (MVC) using one foot.

View Article and Find Full Text PDF

Objective: There is a dearth of research on neuropsychological functioning and the validity of assessment measures in American Indian (AI) older adults. The present study sought to comprehensively examine neuropsychological functioning in cognitively normal AI older adults in the southwestern USA (i.e.

View Article and Find Full Text PDF

HFC-23 (trifluoromethane) is a potent greenhouse gas released to the atmosphere primarily as a by-product of HCFC-22 (chlorodifluoromethane) synthesis. Since 2020, the Kigali Amendment to the Montreal Protocol has required Parties to destroy their HFC-23 emissions to the extent possible. Here, we present updated HFC-23 emissions estimated from atmospheric observations.

View Article and Find Full Text PDF

Pharmacogenomics is central to precision medicine, informing medication safety and efficacy. Pharmacogenomic diplotyping of complex genes requires full-length DNA sequences and detection of structural rearrangements. We introduce StarPhase, a tool that leverages PacBio HiFi sequence data to diplotype 21 CPIC Level A pharmacogenes and provides detailed haplotypes and supporting visualizations for , , and .

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!